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Abstract 
Selecting colorectal cancer (CRC) patients likely to respond to therapy 
remains a clinical challenge. The objectives of this study were to establish which 
genes were differentially expressed with respect to treatment sensitivity and relate 
this to copy number in a panel of 15 CRC cell lines. Copy number variations of the 
identified genes were assessed in a cohort of CRCs. IC50’s were measured for 5-
fluorouracil, oxaliplatin, and BEZ-235, a PI3K/mTOR inhibitor. Cell lines were profiled 
using array comparative genomic hybridisation, Illumina gene expression analysis, 
reverse phase protein arrays, and targeted sequencing of KRAS hotspot mutations. 
Frequent gains were observed at 2p, 3q, 5p, 7p, 7q, 8q, 12p, 13q, 14q, and 17q and 
losses at 2q, 3p, 5q, 8p, 9p, 9q, 14q, 18q, and 20p. Frequently gained regions 
contained EGFR, PIK3CA, MYC, SMO, TRIB1, FZD1, and BRCA2, while frequently 
lost regions contained FHIT and MACROD2.  TRIB1 was selected for further study. 
Gene enrichment analysis showed that differentially expressed genes with respect to 
treatment response were involved in Wnt signalling, EGF receptor signalling, 
apoptosis, cell cycle, and angiogenesis.  Stepwise integration of copy number and 
gene expression data yielded 47 candidate genes that were significantly correlated. 
PDCD6 was differentially expressed in all three treatment responses. Tissue 
microarrays were constructed for a cohort of 118 CRC patients and TRIB1 and MYC 
amplifications were measured using fluorescence in situ hybridisation. TRIB1 and 
MYC were amplified in 14.5% and 7.4% of the cohort, respectively, and these 
amplifications were significantly correlated (p≤0.0001). TRIB1 protein expression in 
the patient cohort was significantly correlated with pERK, Akt, and Caspase 3 
expression. In conclusion, a set of candidate predictive biomarkers for 5-fluorouracil, 
oxaliplatin, and BEZ235 are described that warrant further study. Amplification of the 
putative oncogene TRIB1 has been described for the first time in a cohort of CRC 
patients. 
 
 
 
 
Introduction 
Colorectal cancer (CRC) accounts for 8% of all cancer deaths [1], with variable 
survival of between 39% and 65% depending on stage at diagnosis [2]. The risk of 
developing CRC is dependent on both genetic and lifestyle-related factors and 
increases markedly with age [2]. Although treatment can be curative, a considerable 
proportion of CRC patients have a high risk of disease recurrence after surgery and 
chemotherapy [3]. 
The major pathways implicated in colorectal carcinogenesis include, but are 
not limited to, the PI3K/mTOR pathway, the mitogen-activated protein kinases 
(MAPK) pathway, and the Wnt pathway [4], with the JAK/STAT pathway, Hedgehog 
pathway, and NFκB pathway also involved [5]. These pathways are controlled via 
complex crosstalk, negative feedback, and other compensatory mechanisms. While 
activation of these pathways occurs via mutations in participating oncogenes and 
tumor suppressor genes, respectively, of the 80 somatic mutations in any individual 
CRC, only 15 or possibly less are likely to be essential drivers of tumor initiation, 
progression, and/or maintenance [6]. The most frequently mutated genes in CRC are 
APC (70-80%), TP53 (50%), KRAS (35-45%), PIK3CA (25-32%), BRAF (10-17%) 
and PTEN (4-5%) [7 – 12].   
First line therapy for CRC is usually fluoropyramidine monotherapy and 
oxaliplatin or irinotecan-based chemotherapy [13]. More recently, monoclonal 
antibodies such as cetuximab, panitumumab, and bevacizumab have been licensed 
in combination with chemotherapy for metastatic CRC (mCRC) [14] ( as selective 
and specific anticancer agents with a high therapeutic index and lower toxicity than 
conventional therapies [15]. However, responses to treatment are varied, with less 
than one-third of patients responding to 5-fluorouracil [16]. Although KRAS and 
BRAF mutations indicate resistance to EGFR-targeted therapies, about 40-70% of 
wild type KRAS mCRC patients derive little or no benefit from EGFR-targeted 
therapies [17]. There remains a lack of predictive markers that allow clinicians to 
select patients most likely to benefit from a specific therapy.  
Here, we sought to systematically characterize a panel of CRC cell lines, selected to 
reflect the diversity of this disease, using high-throughput analyses in order to 
identify biomarkers of resistance to both targeted and non-targeted therapies.  
 
 
Methods 
CRC Cell Line Panel 
Fifteen CRC cell lines were studied: the near diploid cell lines DLD-1, HCT116, 
HCT116p53-/-, SW48, and LoVo (all from ECACC except HCT116p53-/- which was 
a gift from Dr G Smith, University of Dundee, UK [18] and the aneuploid cell lines 
SW480, SW837, HT29, T84, Colo 201, Colo 320DM, LS411N, SK-CO-1, NCI H508 
and NCI H716 (all from ATCC) apart from Colo 320DM, T84, and SW837 (all from 
ECACC).  
The cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
(Gibco®, Cat. no. 31885) supplemented with 10% foetal bovine serum (FBS; PAA, 
Cat. no. A15-101) and 1% penicillin-streptomycin (Gibco®, Cat. no.15140-122). The 
cell lines were grown in a humidified incubator at 37°C containing 5% CO2. All the 
cell lines were tested for mycoplasma using the VenorTMGeM Mycoplasma Detection 
Kit (Sigma-Aldrich, Cat. no. MP0025). When the cell lines reached 70-80% 
confluence, they were trypsinized using 0.05% trypsin-EDTA (1X) with phenol red 
(Gibco®, Cat. no. 25300).  
Clinical Samples  
Archival formalin-fixed, paraffin-embedded (FFPE) tissue samples were obtained 
from resection specimens from patients living in Scotland who were diagnosed with 
CRC between 1996 and 2003 and were under 55 years of age at the time of 
diagnosis (refer to S1 Table). A total of 870 patients had been recruited as previously 
described [19]. All cases were reviewed by a gastrointestinal histopathologist prior to 
TMA construction to ensure that the tissue was comprised primarily of tumor. All 
cancers were staged Dukes’ A and B. Cohort material and clinical records access 
was granted by the Tissue Committee, Edinburgh Experimental Cancer Medicine 
(Ref: TR029), Lothian Research Ethics Committee (Ref: 08/S1101/41) and South 
East Scotland HSS (SAHSC) BioResource (Ref: SR117). 
Drug sensitivity assays 
5-fluorouracil (5-FU) 50mg/mL solution for injection was purchased from Medac 
GmbH. Oxaliplatin (L-OHP) 5mg/ml concentrate for solution for infusion (Fresenius 
Kabi Oncology plc, UK) was obtained from the Western General Hospital Pharmacy, 
Edinburgh. The targeted inhibitor BEZ235 (Cat. no. S1009) was purchased from 
Selleck Chemicals. Each 96-well plate consisted of six wells containing cells in 
DMEM supplemented with 10% FBS and 1% penicillin/streptomycin, which served 
as a control. The cells were seeded for 48h prior to addition of the drugs. Eight 
different concentrations were used per drug ranging between 5μM to 100μM (5-FU, 
L-OHP) and between 2.5nM and 80nM, (BEZ235) respectively. The cells were 
incubated with the drugs for 96h. To determine cell viability, 20µL of Alamar Blue 
was added in each well for 6h prior to reading the plates using Fluoroskan Ascent 
FL. All drug sensitivity assays were replicated at least twice and six wells were 
seeded at each drug concentration.  
An average RFU reading was taken for every drug concentration and cell 
viability was calculated as a percentage of the untreated control. Error bars were 
calculated using the correlated standard deviation of the means. The IC50s for 5-FU, 
L-OHP and BEZ235 were determined using the XLfit 5.0 software package (ID 
Business Solutions, UK). No extrapolation was carried out when defining the IC50 
values and outliers were calculated as having a confidence level greater than 0.05. 
DNA, RNA, and protein extraction 
Genomic DNA was extracted from each cell line using DNeasy Blood and Tissue Kit 
(Qiagen, Cat.No. 69504) according to the manufacturer’s instructions. DNA 
concentrations were verified using the NanoDrop 2000 micro-volume 
spectrophotometer (Thermo Scientific). Satisfactory DNA purity was regarded as 
greater than or equal to a 260/280 ratio of 1.8, ensuring minimal protein 
contamination of the sample. The quality of the DNA samples was further assayed 
using agarose gel electrophoresis. After electrophoresis, the gel was carefully 
removed and the DNA bands were visualised using the Gel Documentation System. 
Total RNA was extracted from the cell lines in duplicate using the RNeasy 
MinElute Cleanup Kit (Qiagen, Cat. no. 74204) and miRNeasy Mini Kit (Qiagen, Cat. 
no. 217004). The concentration of the RNA was verified using the NanoDrop 2000 
spectrophotometer. Satisfactory RNA purity was regarded as a 260/230 ratio of 
approximately 2.0. 
Protein lysates were prepared when the cell lines were approximately 80% 
confluent, as described in detail elsewhere [20]. The protein concentration of the 
lysates was determined via the bicinchoninic acid (BCA) assay (Sigma-Aldrich, cat. 
no. C2284-25ML, cat.no. B9643-1L).  
 
KRAS mutation analysis by Sanger sequencing 
Hotspot mutations in codon 12 and 13 were analysed. The primer set was designed 
using Primer Premier® V6.0 software (PREMIER Biosoft International). The primer 
sequences (5' to 3') for KRAS 01 were as follows: GGT ACT GGT GGA GTA TTT 
GAT AGT GT (forward) and TGA ATT AGC TGT ATC GTC AAG GCA CT (reverse). 
KRAS exon 2 amplification was carried out using the HotStar Hi Fidelity Polymerase 
Kit (Qiagen Quality®, cat. no. 202602). The PCR reaction was performed in the DNA 
Engine Opticon 2 Real-Time Cycler (GMI, Inc). The expected length of the PCR 
product was confirmed by the presence of a single band at the appropriate molecular 
weight. Sanger sequencing was carried out at the Medical Research Council Human 
Genetics Unit (MRC-HGU), Edinburgh. Products were sequenced using the ABI 
Prism® 3100 Genetic Analyzer (Applied Biosystems, Hitachi) and data were 
analysed using Mutation Surveyor® DNA Variant Analysis V3.97 software. 
 
 
 
 
 
 
Microarray analyses 
Array comparative genomic hybridization 
Comparative genomic hybridization (CGH) was performed using the NimbleGen 
microarray (Roche). Sample labelling was performed with the NimbleGen Dual-Color 
DNA Labeling Kit (Roche, cat. no. 06 370 250 001). Hybridization was performed in 
the MRC-HGU, Edinburgh using a NimbleGen Hybridization Kit (Roche, cat. no. 05 
583 683 001), NimbleGen Sample Tracking Control Kit (Roche, cat. no. 05 223 512 
001) and two Human CGH 12 x 135K Whole-Genome Tiling Arrays V3.0 (Roche, 
cat. no. 05 520 878 001). NimbleScan software was used to generate the pair report 
files used for copy number data analysis.  The data have been deposited at the 
National Centre for Biotechnology Information (NCBI) Gene Expression Omnibus 
with the accession number GSE72296.   
Gene expression profiling 
Three sets of RNA samples were prepared for Illumina® Whole Genome Gene 
Expression Profiling, where 48,804 transcripts per sample were generated. The 
three sets consisted of two sets of biological replicates and one set of technical 
replicates. All the RNA samples were diluted to a concentration of 500ng/11µl. The 
Illumina® TotalPrepTM RNA Amplification Kit (Ambion®, cat. no. AMIL1791) was 
used to generate biotinylated, amplified RNA for hybridization with the Illumina® 
Human HT-12 v4.0 BeadChip. Prior to progressing with preparation of the RNA 
samples for microarray analysis, the RNA integrity was further assessed with the 
Agilent® 2100 Bioanalyzer using the Agilent® RNA 6000 Nano Kit (Agilent, cat. no. 
5067-1511). Samples with an RNA Integrity Number (RIN) of 7 or better were 
considered acceptable for hybridisation. 
The samples were analysed at the Wellcome Trust Clinical Research Facility, 
Edinburgh (Gene Expression Project - CRF E11960), where they were diluted to a 
concentration of 150ng/µl and hybridized onto three Human HT-12 v4 Expression 
BeadChip arrays. Two technical replicates were hybridized onto each array to serve 
as an internal quality control. The samples were randomly hybridized along the three 
Illumina® HumanHT-12v4 Expression BeadChip arrays. 
Post-hybridization, the arrays were scanned using the Illumina HiScan® 
Platform (Illumina®, cat. no. SY-103-1001). The BeadArray data files were exported 
from the Illumina’s scanning software and imported into the gene expression module 
of the GenomeStudio software (Illumina®), where subsequently the data files were 
transformed to tab delimited files.  The data have been deposited at the National 
Centre for Biotechnology Information (NCBI) Gene Expression Omnibus with 
accession number GSE72544  
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72544) . 
 
Reverse-phase protein arrays 
Reverse-phase protein arrays (RPPA) are a medium-throughput technique that 
allows the screening of samples with a large panel of proteins of interest in a 
relatively short time, while using minimal amounts of both sample and antibodies  
[21]. The denatured and reduced protein samples of the 15 CRC samples were 
spotted in triplicate onto each pad of a 2-Pad FAST® nitrocellulose coated glass 
slide (Whatman Ltd., cat. no. 10485317) using a BioRobotics MicroGrid MG II 
Biobank (Isogen Life Science). Subsequently, they were successfully probed with a 
panel of 31 optimised, in-house validated, total and phospho- antibodies as 
previously described (S2 Table) [20]. These antibodies were selected to target key 
proteins involved in cell proliferation and survival, invasion, metastasis, 
angiogenesis, DNA damage, and apoptosis were optimised and validated via 
Western Blotting. The RPPA spots were quantified using MicroVigeneTM RPPA 
Analysis Module software (VigeneTech Inc.). The data were analysed as previously 
described [22].  
The RPPA spots were quantified using MicroVigeneTM RPPA Analysis Module 
software (VigeneTech Inc.).  
 
 
 
Data analysis 
Genomic data analysis 
Sanger sequencing data were analysed using Mutation Surveyor® DNA Variant 
Analysis Software V3.97 (Soft Genetics®, USA). The raw data files .ab1 generated 
by the ABI Prism® 3100 Genetic Analyzer (Applied Biosystems, Hitachi) were 
imported into the software and the default analysis settings were applied. The 
GenBank annotation files were automatically downloaded and the reference files 
used for mutation detection were automatically synthesised.  
aCGH data were analysed using Partek® Genomic SuiteTM Version 6.6 
(Partek Inc.). The data were initially normalised using Loess Normalization and the 
Genomic Segmentation algorithm was used to analyse the copy number 
amplifications and deletions. The custom segmentation parameters were as follows: 
the minimum genomic markers was 10, the p-value was 0.001, and the signal-to-
noise ratio was 0.03. A region was reported as lost if the log2 copy number ratio was 
below -0.3 and gained if the log 2 copy number ratio was above 0.15. Three different 
region lists were created: (1) regions that were gained in seven or more cell lines; (2) 
regions deleted in seven or more cell lines; (3) those containing the highest 
amplifications, i.e., log2 ratio equal or greater to 1.0 (equivalent to a copy number of 
2). Additionally, genomic segmentation clustering was performed using Euclidean 
distance and average linkage. The copy number analysis was conducted on 
chromosome 1 to chromosome 22 and excluded the two sex chromosomes.  
Transcriptomic data analysis 
The sample gene profile file generated from the gene expression analysis was 
quantile normalised and filtered for those probes where the detection p-value ≤0.05. 
The data were then log2 transformed and mean centred to obtain relative values 
between the cell lines. The sample gene profile file was then annotated using Hg18 
prior to performing differential gene expression analysis (DGEA).  
The DGEA was performed using ArrayMining, an online microarray data 
mining software package [23]. Differential gene expression was conducted using 
SAM analysis to list genes differentially expressed with respect to treatment 
response. Three different analyses were carried out: (1) 5-FU highly sensitive cell 
lines vs. 5-FU less sensitive cell lines, where highly sensitive cell lines were defined 
as having an IC50 ≤ 30µM; (2) L-OHP highly sensitive cell lines vs. L-OHP less 
sensitive cell lines, where highly sensitive cell lines were defined as having an IC50 ≤ 
10µM; (3) BEZ235 sensitive cell lines vs. BEZ235 insensitive cell lines, where 
sensitive cell lines were defined as having an IC50 < 80nM. 
Interpretation of data was accomplished using Functional Annotation 
Clustering in DAVID bioinformatics resources [24].  
 
 
Integration of frequently amplified regions with gene expression 
data 
The gene expression data for the genes located in the frequently gained regions was 
filtered out. Using Pearson’s correlation coefficients with Bonferroni correction, a list 
of genes that had a significant correlation between the log2 copy number value and 
gene expression was generated. The gene expression data for cell lines were 
analysed with respect to treatment response using Mann-Whitney U test using 
GraphPad Prism 6. 
Proteomic data analysis 
Data generated from RPPA were normalised using Cluster 3.0, an open source 
clustering tool [25].  Data were log-transformed, mean centred in Cluster 3.0, and 
clustered by correlation centring and average linkage using MeV 4.8 [26]. RPPA 
results for the 15 CRC panel were analysed with respect to treatment response 
using Mann Whitney U test using GraphPad Prism 6. 
 
Tissue microarray (TMA), automated quantitative analysis 
(AQUA), and FISH  
Five-micron haematoxylin and eosin-stained slides were prepared from the FFPE 
blocks, and tumor areas were marked by a pathologist and a trained research 
technician. Following histopathological examination, 118 cases were chosen out of 
the original cohort and a tissue microarray (TMA) was constructed by a qualified 
technician. Four biological replicates (TMA000034A-D) were constructed as 
described in detail elsewhere [27] and cut into 5µm sections using a microtome and 
mounted onto glass slides. Clinical and pathological parameters of this cohort are 
summarised in S1 Table. 
Protein expression of TRIB1 was assessed with anti-TRIB1 rabbit polyclonal 
antibody in the CRC TMA using Automated QUantitative Analysis (AQUA), described 
in detail elsewhere [28,29]. TRIB1 expression in both the cytoplasmic and nuclear 
compartments was subsequently correlated with other proteins previously measured 
in this cohort. TRIB1 expression was also investigated with respect to patient 
survival, as described below. 
TRIB1 and MYC amplification in the CRC patient cohort were investigated 
using fluorescence in situ hybridisation (FISH). A MYC/CEN8p probe was purchased 
from Abnova (cat. no. FG0065) and the TRIB1/CEN8p probe was custom designed 
by Abnova. The protease treatment time was varied to optimise digestion and ensure 
good quality hybridisation. Visualisation was performed using DAPI (4,6-diamidino-2-
phenylindole-2-hydrochloride (Abnova) to stain nuclei. 
Ready-to-use dual-labelled probes for MYC and TRIB1 were purchased from 
Abnova. The MYC/CEN8p FISH probe consisted of an ~160kb MYC probe located at 
8q24.12-q24.13 with a Texas Red fluorophore together with an ~520kb CEN8p 
probe located at 8p11.21 with a FITC fluorophore. The TRIB1/CEN8p FISH probe 
consisted of an ~260kb TRIB1 probe located at 8q24.13 with a Texas Red 
fluorophore together with an ~520kb CEN8p probe located at 8p11.21 with a FITC 
fluorophore.  
Scoring was carried out by a trained technician and a consultant pathologist. 
The slides were scored using a Leica DMLB fluorescent microscope using 100X oil 
immersion lens. The Colorado Scoring Criteria were used [30] to score the TMA 
slides. A maximum of twenty nuclei per core were scored in most cases, although in 
some cases a minimum of ten nuclei were scored due to not having twenty scorable 
nuclei. The sum of the red and green fluorophores was noted for each core, and the 
final score consisted of the ratio of the red fluorophore to the green fluorophore. 
FISH scores less than 1.8 were interpreted as negative [31].  
 
Statistical analyses 
TRIB1 protein expression data generated from AQUA analysis were correlated with 
AKT, caspase 3, cyclin B1, ERK, Ki67, MYC, S6, PTEN, pAKT, pERK, pHistone H3, 
pMEK, and pS6 protein expression. Statistical analysis was carried out using 
Pearson’s correlations, and p-values were adjusted for multiple testing using the 
Bonferroni correction. An open source programme TMA Navigator 
(http://www.tmanavigator.org/) was used for statistical analysis. Survival analysis for 
TRIB1 and MYC amplification in the CRC cohort was carried out using GraphPad 
Prism 6. 
 
Results 
Single gene mutational analysis is insufficient for 
stratification of tumors with respect to therapy 
After treatment with 5-fluorouracil (5-FU) for 96 h, thirteen CRC cell lines showed 
varying degrees of sensitivity when treated with drug concentrations ranging from 
2.5µM to 100µM (Fig. 1A). Two CRC cell lines (Colo320DM, T84) were insensitive to 
5-FU at a concentration of 100µM. The IC50 values for 5-FU ranged from 3.1 to 
>100µM with a median of 19.6µM. The most sensitive cell lines were HT29, LS411N, 
and HCT116. DLD-1, HCT116, HCT116p53-/-, SW48, and LoVo are reported to be 
mismatch repair deficient [32].  This profile of mismatch repair status did not 
correlate with 5-FU sensitivity (p = 0.713; Mann-Whitney U test) contrary to a study 
by Bracht and colleagues [33].  
Although a number of in vitro studies have suggested that TP53 deficiency 
contributes to drug resistance [34], we failed to see an association (p = 0.238; Mann-
Whitney U test). HT29, LS411N, HCT116 p53-/-, SW837, NCI H508, NCI H716 are 
all TP53 deficient (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/), but 
they were still sensitive to 5-FU in this study. Mariadason et al., however, reported 
no difference in 5-FU-induced apoptosis in mutant and wild type p53 cell lines [35].   
After treatment with oxaliplatin (L-OHP) for 96 h, the CRC cell lines showed 
varying degrees of sensitivity when treated with increasing concentrations of L-OHP 
ranging from 2.5µM to 100µM (Fig. 1B). The IC50 values for L-OHP ranged from 3.0 
to 31.1µM, with a median of 8.0 µM, demonstrating a ten-fold range of sensitivity. 
The most sensitive cell lines were HT29, LS411N, and SW837, while the least 
sensitive were Colo320DM, NCI H716, and Colo201. No statistical significance (p = 
0.462; Mann Whitney U Test) was observed when comparing L-OHP IC50 values 
between dMMR cell lines and pMMR cell lines, which is in agreement with a similar 
study by Fink et al. [36].   
There was no association between p53 status and L-OHP IC50 values (p = 
0.187; Mann Whitney U Test), in contrast to a previous report [37].  However, a 
recent study carried out in 51 advanced CRC patients concluded that TP53 
mutational status was not associated with benefit from first-line oxaliplatin-based 
treatment [38].   
Seven CRC cell lines were sensitive and eight CRC cell lines were insensitive 
to treatment with various concentrations (2.5nM and 80nM) of BEZ235 for 96 h (Fig. 
1C). The IC50 values for BEZ235 ranged from 13.4 to >80nM, with the sensitive cell 
lines having a median sensitive concentration of 23.6nM. The most sensitive cell 
lines were HT29, Colo201, and NCI H716, while NCI H508, T84, SW48, SW480, 
Colo320DM, HCT116, HCT116 p53-/-, and LoVo were insensitive at a concentration 
of 80nM. No statistically significant difference was observed (p = 0.346; the Mann-
Whitney U test) between the IC50 values for BEZ235 treatment and PIK3CA mutant 
and wild type groups. All the PI3KCA mutant cell lines had either a BRAF or a KRAS 
co-mutation. No COSMIC data was available for MTOR mutations in these cell lines 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). Serra et al. established 
that BEZ235 arrested proliferation in all 21 cancer cell lines used in their study, 
independent of PI3K pathway mutation status [39],  and that cell lines with a BRAF 
or KRAS mutation or EGFR amplification were slightly less sensitive to BEZ235 
compared to the other cell lines [39].   
Of the 15 CRC cell lines, eight cell lines possessed KRAS exon 2 mutations. 
The DLD-1, HCT116, HCT116 p53-/-, and LoVo cell lines had a 5574 G>A 
substitution consistent with a G13D missense mutation; the SK-CO-1 and SW480 
cell lines had a 5571 G>T substitution consistent with a G12V missense mutation; 
SW837 had a 5570 G>T substitution consistent with a G12C mutation; and T84 had 
a 5574 G>A substitution consistent with a G13D mutation. This is in agreement with 
published sequencing data and data in the COSMIC database 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). There were no 
statistically significant differences in response to 5-FU, L-OHP, and BEZ235 with 
respect to KRAS mutational status (p = 0.98, p = 0.60, and p = 0.17, respectively). 
Unsupervised hierarchical clustering for the IC50 values for 5-FU, L-OHP, and 
BEZ235 using Pearson’s correlations with complete linkage showed that the cell 
lines did not cluster according to any particular mutation. There was variability in 
response to the three different treatments (Fig. 1D).  
 
Chromosomal regions frequently gained and lost in the 
colorectal cancer cell lines 
The panel of cell lines was next evaluated by aCGH to identify common 
chromosomal regions of gain and loss. Twenty-four regions were frequently gained 
in at least 7/15 CRC cell lines. Frequent gains were observed at 2p, 3q, 5p, 7p, 7q, 
8q, 12p, 13q, 14q, and 17q (Fig. 2) (Table 1). On the other hand, a total of 14 
regions were lost in at least 7/15 CRC cell lines (Table 2). Frequent losses were 
observed at 2q, 3p, 5q, 8p, 9p, 14q, 18q, and 20p (Fig. 2). These regions of gain and 
loss were similar to those previously reported [32, 40 – 44].  
Hierarchical clustering of the segmented copy number data using Euclidean 
distance average linkage resulted in two major clusters: one cluster contained NCI 
H716 while the other cluster contained the other 14 cell lines (Fig. 3). One of the 
sub-clusters contained HT29, SW48, LS411N, LoVo, HCT116, and HCT116p53-/-. 
HCT116, HCT116p53-/-, SW48, and LoVo are near-diploid and known to have 
mutations in MMR genes MLH1 and MSH2 [45, 46].  The other near-diploid cell line, 
DLD-1, also clustered separately. This cell line is MMR deficient in MSH6 [47].  
Differential gene expression with respect to drug 
sensitivity 
Genes differentially expressed with respect to 5-FU sensitivity are listed in S3 Table 
and depicted in a heat map in Fig. 4A. Functional annotation using DAVID [24] 
revealed that these genes were mainly involved in cell cycle (TAF2, CHFR, CCND2, 
OSGIN2, TERF1, TBRG4), focal adhesion (ABCB1, SH3KBP1, EBAG9), apoptosis 
(SHRKBP1, EBAG9, TERF1, TBRG4), and regulation of transcription (LASS2, 
LMCD1, MAF1, TAF2, THAP11, CHURC1, MED14, PIAS3, PURB, TERF1, ZNF239, 
ZNF7). Important KEGG pathways associated with 5-FU mode of action and 
subsequently enriched in the list originating from this study included purine 
metabolism (NT5C2, POLR2J2), pyrimidine metabolism (NT5C2, POLR2J2), drug 
metabolism (GSTO2), ABC transporters (ABCB1), and oxidative phosphorylation 
(NDUFA9).  
Genes differentially expressed with respect to L-OHP sensitivity were involved 
with DNA binding (GLI2, GLI4, SETDB2, NFXL1, POLE4, PURA, TSNAX, ZBTB41, 
ZNF20, ZNF254, ZNF420, ZNF689, ZNF7, ZNF91), regulation of transcription (GLI2, 
NFXL1, PURA, TGFBRAP1, ZBTB41, ZNF20, ZNF254, ZNF420, ZNF689, ZNF7, 
ZNF91), regulation of cell cycle (CHFR, RPS27L, SCRIB, TPR), and apoptosis 
(BFAR, EIF2AK2, SCRIB, TNFSF9) (S4 Table  and Fig. 4B). Oxidative 
phosphorylation (ATP6V1B2), Jak-STAT signalling pathway (CBLC), hedgehog 
signalling pathway (GLI2), glycolysis (AKR1A1), glutathione metabolism (GSTO2), 
drug metabolism (GSTO2), cysteine and methionine metabolism (MTAP), MAPK 
signalling pathway (MAP3K2, MAP4K2), base excision repair, and nucleotide 
excision repair (POLE4) pathways were enriched in this gene set.  
The most differentially expressed genes with respect to BEZ235 sensitivity 
were involved in glucose metabolism (CPS1, G6PD, PYGL), cell death (TRIAP1, 
ERN2, LYZ, MUC5AC, PPT1, PTRH2, RNF216), response to drug (TIMP4, AACS, 
CPS1), chromatin organization (BCORL1, LOC644914, LOC440926, H3F3A, 
SMARCC1, TBL1XR1), regulation of transcription (BCORL1, LMCD1, SPDEF, 
SMARCC1, TAF4B, CHURC1, ERN2, PROX1, SORBS3, TBL1XR1, ZNF75A), and 
DNA binding (LOC644914, LOC440926, H3F3A, SPDEF, SMARCC1, TAF4B, 
MSRB2, NUCB1, PROX1, TBL1XR1, ZNF75A) (Fig. 4C and S5 Table). The Wnt 
signalling pathway (LRP5, TBL1XR1), phosphatidylinositol signalling system 
(PIK3C2B), and the Jak-STAT signalling pathway (SPRY1) were enriched in less 
sensitive cell lines. 
 
Integration of frequently amplified regions with gene 
expression data  
A total of 971 genes were located in frequently gained regions, of which 
corresponding gene expression data were available for 667 genes. A total of 47 
genes were significantly correlated and are listed in Table 1, suggesting that at least 
7% of the genes found in the frequently gained regions might be regulated by copy 
number changes, at least in part. This is important since genes that are over-
expressed when amplified are more likely to be putative oncogenic drivers and 
therapeutic targets [48]. These amplified and overexpressed genes were involved in 
pathways in cancer, colorectal cancer drug metabolism, cell cycle, homologous 
recombination, DNA replication, nucleotide excision repair, mismatch repair, 
apoptosis, p53 signalling, MAPK signalling, ErbB signalling, wnt signalling, TGF-beta 
signalling, and JAK-STAT signalling by pathway analysis. 
20/47 of these genes were associated with treatment responses (Fig. 5 and 
Fig. 6). Significant differences were found between response to 5-FU treatment and 
gene expression of TBRG4 (p ≤ 0.001), MRPL32 (p ≤ 0.001), CYCS (p ≤ 0.001), 
PDCD6 (p = 0.01), COBL (p = 0.01), DDX56 (p = 0.01), MRPS17 (p = 0.01), PDS5B 
(p = 0.03), TOMM7 (p = 0.03), AEBP2 (p = 0.04), NOD1 (p = 0.04), MIR1204 (p = 
0.04) and RFC3 (p = 0.05). Significant differences were found between response to 
BEZ235 treatment and gene expression of PDCD6 (p = 0.002), MYC (p = 0.01), 
MRPL32 (p = 0.01), TBRG4 (p = 0.03) and PURB (p = 0.04). Significant differences 
were found between response to L-OHP treatment and gene expression of PDS5B 
(p < 0.005), UBL3 (p = 0.01), MTIF3 (p = 0.02), CASC8 (p = 0.02), XPO4 (p = 0.04), 
GTF3A (p = 0.04) and PDCD6 (p = 0.04). 
 
 Proteomic analysis 
Reverse phase protein array (RPPA) was used to measure protein expression of 31 
phosphorylated and non-phosphorylated proteins in the CRC cell lines. Two main 
sub-clusters were produced by unsupervised hierarchical clustering of RPPA data 
(Fig. 7). Sub-cluster one was enriched in proteins regulating cell-cycle function 
(Chk1, Chk2, p38MAPK, p21, p27, and Ki67; p=0.037). Sub-cluster two was 
enriched for proteins regulating cell migration (Bcl-2, ErbB1, HIF-1 alpha, PTEN, 
TRIB1; p=0.0007), phosphorylation (Bcl-2, cyclin D1, ErbB1, mTOR, PTEN, TRIB1; 
p=0.001), cell proliferation (Bcl-2, β-catenin, cyclin D1, ErbB1, HIF-1 alpha, mTOR, 
PTEN, TRIB1; p=0.0003), cellular responses to stress (Bcl-2, cdc2, cyclin D1, HIF-1 
alpha, TRIB1; p=0.001), negative regulation of apoptosis (Bcl-2, cdc2, ErbB1, PTEN, 
B-raf; p=0.005), and focal adhesion (β-catenin, Bcl-2, B-Raf, cyclin D1, ErbB1, 
PTEN; p=0.00013). 
 
Difference in protein expression with respect to treatment 
responses 
Significant differences in protein expression were found for FAK (p = 0.004) and 
phospho MEK (p = 0.005) with respect to 5-FU treatment responses (Fig. 8A). 
Significant differences in gene expression were found for cdc2 (p = 0.03), FAK (p = 
0.0003), Ki67 (p = 0.009), MEK (p = 0.002), NFκβp65 (p = 0.02), and PTEN (p = 
0.0006) with respect to L-OHP treatment responses (Fig. 8B). No significant 
differences were observed for RPPA values with respect to response to BEZ235. 
 
TRIB1 in CRC 
Statistically significant correlations between copy number gains and gene expression 
were identified on amplicons located on chromosome 8. Candidate genes that could 
be investigated further included TRIB1, which was also observed to be recurrently 
amplified and overexpressed in a CRC study carried out by Camps et al. [41]. 
Furthermore, an integrated analysis of genomic and transcriptomic profiles of a panel 
of breast cancer cell lines established that TRIB1 is a potential amplicon driver [49]. 
TRIB1 has also been implicated as a key oncogene in acute myeloid leukaemia and 
ovarian cancers [50].  This region is 2.25Mb away from MYC, a well-established 
oncogene, including in CRC. TRIB1 was chosen as a candidate gene for further 
investigation due to the fact that seven out of fifteen cell lines exhibited copy number 
gain. The gene is located at Chr8: 126,393,571- 126,567,050, in the 8q24 region, 
known to be associated with breast, ovarian, prostate and colorectal cancer [51]. 
TRIB1 is reported to be amplified in two integrated genomics and transcriptomic 
profiling studies on CRC cell lines and breast cancer cell lines, whereas in the latter 
TRIB1 was highlighted as a potential additional amplicon driver [41, 49]. 
Furthermore, the tribbles protein family act as adaptors that interact with the MAPK 
pathway [52], one of the most critical for cellular proliferation [53], transformation, 
differentiation [54], apoptosis, autophagic type II programmed cell death, and 
senescence [55]. In view of this pathway being centrally involved in cellular decision-
making, small quantitative differences in pathway components may be sufficient to 
cause large changes in cellular phenotype [56].  
 
Genomic, transcriptomic, and proteomic data for TRIB1 in 
the CRC cell line panel 
There was a weak correlation between DNA copy number of the TRIB1 region (Chr8: 
126,393,571- 126,567,050) and mRNA expression of TRIB1 (r2 = 0.395, p = 0.012). 
The TRIB1 region was gained in seven cell lines and clearly amplified and very 
highly expressed in NCI H716 cells. Reverse phase protein array (RPPA) analysis of 
TRIB1 was carried for the cell lines, which did not reveal a correlation with log2 copy 
number ratio (r2 = 0.209, p = 0.09) or with gene expression (r2 = 0.089, p = 0.282). 
Nevertheless, a large variation between TRIB1 protein expression was observed 
between the different cell lines that did not reach statistical significance.  
 
TRIB1 and MYC amplification in the clinical cohort using 
FISH 
The Oncomine(R) [57] database was interrogated to explore TRIB1 copy number in a 
cohort of 881 CRC patients (TCGA Colorectal 2), where TRIB1 was found to be 
gained in 11% of primary CRC samples. Consequently, the amplification of TRIB1 
and MYC in the tissue microarray consisting of 118 Dukes’ A and B CRC patients 
was analysed.  
Of the 118 cores (each representing a case), a total of 76 cores contained 
nuclei that could be scored for TRIB1. FISH scores for TRIB1 ranged between 0.45 
and 3.38 (median 1.00, IQR 0.28; mean 1.21, SD 0.52). Of 76 cases, 11 tumors 
(14.4%) were amplified (a score of ≥1.8). 
Of 118 cores, a total of 81 cores contained nuclei that could be scored for 
MYC. FISH scores for MYC ranged between 0.70 and 4.14 (median 1.02; IQR 0.24; 
mean 1.17, SD 0.52). Six tumors were amplified for MYC (7.4%).  
TRIB1 and MYC FISH scores were strongly positively correlated (Spearman’s 
Rank; r2= 0.783, p = 0.0001).  
 
TRIB1 protein expression using AQUA and associated 
pathway expression 
TRIB1 protein expression was next investigated using AQUA. Protein expression in 
the cytoplasm and nucleus was successfully measured in 96 out of 118 cases. Five 
samples out of the 96 samples showed TRIB1 overexpression (5.2%) in the 
cytoplasm when considering a cut-off of two standard deviations, while 6/96 showed 
TRIB1 overexpression (6.25%) in the nucleus. 
 
Of 22 proteins in the MAPK pathway, TRIB1 protein expression in the 
cytoplasm was significantly correlated (p = 0.05) with TRIB1 (nucleus), phospho-Erk, 
Akt, Myc (nucleus), PTEN (cytoplasm), cleaved caspase 3 (nucleus), and phospho-
MEK (nucleus), after correcting for multiple testing. TRIB1 protein expression in the 
nucleus was significantly correlated (p = 0.05) with TRIB1 (cytoplasm), Akt, phospho-
Erk, and Myc (nucleus), after correcting for multiple testing (Fig. 9). There was no 
statistically significant difference in survival between patients with TRIB1 or MYC 
amplifications and those without. 
 
 
Discussion  
Although the mutation status of a number of individual candidate genes has been 
associated with responses to CRC therapy, the results are inconclusive and few 
have resulted in useful stratification biomarkers. Here, the cellular response to 
treatment with 5-FU, L-OHP and BEZ235 was not associated with the mutational 
status of common genes in multiple cell lines. The measurement of a mutation in a 
single gene alone was insufficient to stratify patients for CRC therapy, which argues 
for adopting a multi-scale approach to help identify other factors that contribute to 
therapeutic resistance. 
 
The list of tumor suppressor genes found in this study’s frequently deleted 
regions included BCL2, DCC, CTDP1, SMAD2, and FHIT [58 – 60]. Although BCL2 
is not usually considered to be a tumor suppressor gene, it has been reported to act 
as one under certain circumstances [61].  Furthermore, one of the frequently deleted 
regions contained MACROD2 at 20p12.1 which was also described in a recently 
published study by Linnebacher et al. [62].   
 
Systematic analysis of copy number gains allowed us to identify regions that 
were gained in seven or more cell lines. The use of a high-resolution array allowed 
analysis of frequently amplified regions that contained less well described genes. 
This analysis, when combined with gene and protein expression analysis and 
extensive literature review, helped us to identify a number of genes that could be 
further investigated as possible novel oncogenic drivers and determinants of 
response to therapy.  
 
A number of genes were amplified, overexpressed, and associated with 
therapeutic responses. By adopting a functional multiscale analytical approach, a list 
of 20 candidate predictive biomarkers for 5-FU, L-OHP, and BEZ235 was generated. 
5-FU-sensitive cell lines had higher programmed cell death 6 (PDCD6) gene 
expression than less sensitive cell lines. PDCD6, located on cytoband 5p15.33-
p14.1, is known to be involved in apoptosis survival [63] and is implicated in 
migration and invasion in ovarian cancers [64].  Furthermore, there was a statistically 
significant difference with respect to treatment responses for the three treatments 
examined in this study. It has recently been demonstrated that PDCD6 accumulates 
in the nucleus and induces apoptosis in response to DNA damage [65]. Moreover, 
Rho and colleagues found that over-expressed PDCD6 inhibits angiogenesis 
through the PI3K/mToR/p70S6K pathway by interacting with VEGFR-2 [66], while 
Park et al. showed that PDCD6 exerts its anti-tumor potency by activating the p53-
p21 protein for G1 phase of cell cycle progression and apoptosis involved in human 
ovarian tumorigenesis. This study suggested that suppressing PDCD6 supports 
tumorigenesis by inhibiting apoptosis in ovarian cancer [67].   
 
Expression of TBRG4, MRPL32, CYCS, COBL, DDX56, MRPS17, PDS5B, 
TOMM7, AEBP2, NOD1, MIR1204 and RFC3 was lower 5-FU-sensitive cell lines.  
CYCS, TOMM7, NOD1, MRPL32, DDX56, TBRG4, COBL, and MRPS17 all map to 
the 7p21.1 - 7p11.2 cytoband. Their biological functions include positive regulation of 
cell proliferation  and cell cycle arrest  [68]. The Nod1 signalling complex has been 
shown to drive JNK activation, cytokine release, and induction of apoptosis in MCF7 
breast cancer cells [69].  7p21.1 - 7p11.2 cytoband amplification may in itself be, 
associated 5-FU responses by chromosomal-scale changes biasing expression over 
a large region and affecting genes that do not confer selective advantage [70].  
Moreover, EGFR maps to this cytoband.      
  
PDS5B has been shown to modulate homologous recombination in breast 
cancer and influence responses to DNA damaging agents [71].  Furthermore, they 
speculated that low PDS5B-expressing tumors are more responsive to DNA 
damaging chemotherapy [71]. RFC3 copy number gains are frequently found in 
colon and oesophageal cancers, and in the latter cancer, Lockwood and colleagues 
showed that RFC3 knockdown inhibited proliferation and anchorage-independent 
growth [72].  Furthermore, RFC3 gene expression was one of the most differentially 
expressed between normal and tumor tissue [73].  RFC3 is also involved in DNA 
synthesis and repair [74].  MiR1204, located on chromosome 8q24, may be 
associated with tumor growth suppression [75, 76], perhaps in a partially p53-
dependent manner [77].  AEBP2 is involved in DNA binding [78].   
 
PDCD6 gene expression was higher in cells sensitive to L-OHP, while 
expression of PDS5B, UBL3, MTIF3, XPO4, CASC8, and GTF3A was lower. UBL3 
was identified as one of seven genes that predict relapse and survival in early-stage 
cervical carcinoma patients [79].  XPO4, a critical protein synthesis regulator, is 
implicated in the regulation of Smad signalling [80].   
 
PDCD6 gene expression was, once again, greater in BEZ235-sensitive cell 
lines, while MYC, MRPL32, TBRG4, and PURB was lower. The frequent association 
of PDCD6 gene expression with drug response supports future studies to explore the 
significance of this gene with respect to drug response. A number of in vitro and in 
vivo studies in breast and prostate cancer have demonstrated that MYC amplification 
or phosphorylation lead to acquired resistance to BEZ235 [81], and Tan and 
colleagues used a PDK1 inhibitor to bypass MYC-dependent resistance [81].  
Genomic amplification of MYC or eIF4E contributed to resistance to BEZ235 in 
mammary epithelial cells [82].  MRPL32, TBRG4, and PURB all mapped to 
chromosome 7p14.2-p11.2. Chromosome 7p gains have been observed in both the 
early- and late-stage CRC [83].  TBRG4 is involved in positive regulation of cell 
proliferation and cell cycle arrest [68] and apoptosis [84].   
 
Seven proteins were associated with responses to cytotoxic therapies, but no 
differential expression was seen with the PI3K/mTOR inhibitor. For example, focal 
adhesion kinase (FAK) was differentially expressed between 5-FU and L-OHP 
groups. FAK is associated with apoptosis and proliferation pathways in cancer cell 
lines [85]. Cdc2 was similarly differentially expressed between L-OHP very sensitive 
and less sensitive cell lines. CDK1 (which codes for cdc2) loss elicited 
chemotherapeutic resistance in lung cancer [86], while cdc2 was differentially 
expressed in a study of responses to L-OHP three CRC cell lines [87].   
 
As proof of concept of adopting a functional multi-scale analytical approach to 
comprehend the underlying changes driving colorectal carcinogenesis, a gene that 
was frequently amplified, TRIB1, was selected for further analysis as a candidate 
biomarker. There was a highly statistically significant correlation between the FISH 
score of TRIB1 and MYC (r2 = 0.783, p = 0.0001), consistent with co-amplification. A 
number of studies have suggested that MYC-driven cancers are reliant on other 
genes and pathways, unlike non-MYC-driven cancers [88 – 90].  Toyoshima and 
colleagues identified a set of 102 genes required for survival of c-MYC over-
expressing cells using a high-throughput siRNA screening approach (91), which 
included TRIB1. Furthermore, TRIB1 appears to be druggable, involved in oncogenic 
pathways, and differential toxicity. Gene expression silencing of TRIB1 using 
deconvoluted siRNA pool-mediated knockdown resulted in increase in cleaved 
caspase 3 and 7 and in increase of γ-H2AX foci in c-MYC expressing human 
foreskin fibroblasts but not in the control fibroblasts [91]. 
   
We speculate that MYC and TRIB1 are co-amplified in a number of CRC 
patients and that targeting TRIB1 would lead to cell death via a synthetic lethal 
mechanism. Since MYC cannot be therapeutically targeted, it would be useful to 
investigate the function of TRIB1 and its role in targeted therapy. MYC is known to 
interact with a number of signalling pathways and is mostly involved in growth and 
proliferation. Furthermore, although MYC is prominently referred to as a proto-
oncogene, MYC also exhibits pro-apoptotic properties [92].  It is feasible that in a 
subset of CRCs, when TRIB1 is targeted, MYC might function as a tumor suppressor 
gene leading to cell death. This would need to be validated in a series of functional 
experiments. 
 
In addition, TRIB1 protein expression was significantly correlated with MYC, 
phosphorylated MEK, ERK, total Akt, PTEN, and cleaved caspase 3, consistent with 
previous findings that TRIB1 interacts with MEK1 and overexpression leads to ERK 
phosphorylation [93].  Furthermore, a number of studies have observed that TRIB1 is 
predominantly, but not exclusively, located in the nucleus, as here [52].  Both TRIB2 
and TRIB3 have interact with Akt, mainly by inhibition, but no data has yet been 
published for TRIB1 [94].  These data must be interpreted with caution but it would 
be interesting to investigate the involvement of TRIB1 in the MAPK and PI3K/Akt 
pathway. 
 
Although a difference in TRIB1 expression was observed in the cell line panel, 
there was no statistically significant correlation between gene and protein 
expression. This could have occurred for a number of technical, statistical, and 
biological reasons including assay sensitivity, array probe specificity, mRNA and 
protein degradation [95], and sample numbers. Sharova and colleagues confirmed 
that TRIB1 has an mRNA half-life of less than one hour, in spite of the median 
estimated half-life being 7.1 hours [96].  This finding sheds some light on the 
functional role of TRIB1, in that the half-life is related to its physiological role and 
usually found in transcription factors and genes involved in cell cycling [97].  
Additionally, a number of transcripts encoding regulatory proteins are known to 
undergo rapid mRNA decay [98]. 
 
This study has a number of limitations. Further data analysis needs to be 
performed with respect to frequently deleted regions to identify putative tumor 
suppressor genes involved in CRC and their relationship with treatment responses. 
This study used continuous cancer cell lines, which may not fully represent parent 
tumors and, therefore, clinical responses to therapy. Nevertheless, cell lines have 
been shown to recapitulate the molecular and phenotypic characteristics of primary 
tumors [99 – 101], including in colorectal cancer [102], and therefore have value in 
translational studies and biomarker discovery. Finally, the tumors analysed in the 
clinical cohort were derived from patients less than 50 years of age and might not be 
fully representative of the wider CRC population. Further validation is required in a 
larger, more representative clinical cohort. 
 
 
Conclusions 
 
Our multi-scale analytical approach has generated a list of 20 candidate predictive 
biomarkers for 5-FU, L-OHP, and BEZ235. This approach is valuable for 
understanding the mode of action of different treatments and guiding personalised 
therapy. Furthermore, we show, for the first time, that TRIB1 is co-amplified with 
MYC in a proportion of CRCs and may be an attractive target for intervention in this 
group of patients.  
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Table 1.  Summary of the regions of copy number gains and the genes significantly 
overexpressed in those regions (* after Bonferroni correction) 
   Cell lines containing amplicons Cytoband Starting 
bp 
Ending bp Size 
(Mb) 
aCGH copy 
number 
gains range 
(log2 ratio) 
Significantly correlated 
over-expressed genes found 
in the amplicon* 
Colo201, Colo320DM, HCT116, HCT116 p53-
/-, HT29, LS411N, LoVo, NCI H508, NCI 
H716, SK-CO-1, SW480, SW837, T84       
2p11.2 88,741,497 89,240,74
2 
0.5 0.2 – 1.1  
Colo320DM, HT29, LS411N, NCI H508, NCI 
H716, SW480, T84 
3q26.32 180,172,61
8 
180,364,4
15 
0.02 0.2 – 0.6  
Colo201, Colo320DM, HT29, LS411N, NCI 
H508, SW480, T84              
3q27.1 185,357,49
9 
185,500,0
05 
0.14 0.2 – 1.2  
Colo320DM, HCT116, HCT116 p53-/-, HT29, 
LS411N, NCI H508, SW480, T84              
3q28 190,361,01
8 
190,756,7
66 
0.4 0.2 – 0.7  
Colo201, Colo320DM, HT29, LS411N, NCI 
H508, SW480, T84              
3q29 198,737,46
5 
198,973,7
65 
0.24 0.2 – 0.7  
Colo201, HT29, LS411N, LoVo, NCI H508, 
NCI H716, SK-CO-1, SW480            
5p15.33-
p14.1 
144,656 25,059,98
8 
24.9
2
0.2 – 0.7 PDCD6 
Colo201, LoVo, NCI H508, NCI H716, SW48, 
SW480, T84              
7p22.3 959,839 1,554,223 0.59 0.3 – 0.8  
DLD-1, LoVo, NCI H508, NCI H716, SW48, 
SW480, T84              
7p21.3 10,059,941 10,462,00
6 
0.40 0.2 – 1.1  
Colo201, LS411N, LoVo, NCI H508, NCI 
H716, SW48, SW480, T84              
7p21.1-
p14.2 
19,159,609 36,992,54
1 
13.3
5 
0.3 – 0.9 CYCS, TOMM7, MIR196B, 
NOD1 
Colo201, LS411N, LoVo, NCI H508, NCI 
H716, SK-CO-1,  SW48, SW480, T84              
7p14.2-
p11.2 
37,182,752 56,225,01
5 
19.0
4 
0.2 – 0.6 MRPL32, DDX56,PURB, 
TBRG4,COBL, 
LANCL2,MRPS17 
LS411N, LoVo, NCI H508, SK-CO-1, SW48, 
SW480, T84              
7q11.22 69,497,636 71,538,67
3 
2.04 0.2 – 0.3  
Colo201, DLD-1, HT29, LS411N, LoVo, NCI 
H508, NCI H716, SK-CO-1, SW48, SW480, 
T84      
7q11.23-
31.1 
76,596,876 110,404,5
88 
33.8
1 
0.2 - 1.1 TMEM60, CLDN12, SHFM1, 
LMTK2, PTCD1,PLOD3, 
ZNHIT1, ARMC10, RINT1, 
BCAP29, SLC26A4, 
 
 
 
Cell lines containing amplicons Cytoband Starting 
bp 
Ending bp Size 
(Mb) 
aCGH 
copy 
number 
gains 
range 
(log2 ratio) 
Significant correlated over-
expressed genes found  in 
the amplicons* 
LS411N, LoVo, NCI H508, NCI H716, SK-CO-
1, SW48, T84              
7q31.1-
q31.31 
110,930
,968 
119,328,807 8.4 0.2 – 0.6 ST7 
Colo201, HCT116 p53-/-, LS411N, LoVo, NCI 
H508, NCI H716, SK-CO-1, SW48            
7q31.33-
q34 
124,724
,896 
138,981,311 14.2
6 
0.2 – 1.0 IMPDH1, CHCHD3, NUP205, 
KIAA1549, LUC7L2 
Colo201,LoVo, NCI H508, NCI H716, SK-CO-
1, SW48, T84              
7q35 146,954
,947 
147,418,309 0.46 0.2 - 0.6  
Colo201, Colo320DM, HCT116, HCT116 p53-
/-, HT29, NCI H716, SK-CO-1, SW480, 
SW837              
8q24.13-
q24.21 
126,328
,971 
128,964,088 1.46 0.3 – 4.2 NSMCE2, TRIB1, FAM84B, 
LOC727677, MIR1204, MYC 
Colo201, Colo320DM, HCT116, HCT116 p53-
/-, HT29, SK-CO-1, SW480          
8q24.21 129,068
,127 
129,110,839 0.04 0.3 – 3.4  
Colo201, LS411N, LoVo, NCI H716, SW480, 
SW837, T84              
12p13.3 33,393 185,534 0.15 0.2 – 0.6  
Colo320DM, LS411N, LoVo, NCI H716, SK-
CO-1, SW480, SW837, T84              
12p12.3-
p12.2 
15,652,
223 
20,311,064 4.66 0.2 – 1.5 STRAP, AEBP2 
Colo201, Colo320DM, HT29, LS411N, NCI 
H508, NCI H716, SK-CO-1, SW480           
13q12.11-
q13.3 
18,761,
622 
 
35,141,488 16.3
8 
0.2 – 3.39 MPHOSP8, N6AMT2, XPO4, 
GTF3A, MTIF3, POMP, UBL3, 
BRCA2, PDS5B, RFC3 
Colo201, Colo320DM, DLD-1, HT29, LS411N, 
NCI H508, SW480              
13q14.11 42,472,
749 
42,745,298 0.27 0.2 – 0.8  
Colo201, Colo320DM, HCT116, HCT116 p53-
/-, HT29, LS411N, LoVo, NCI H508, NCI 
H716, SK-CO-1, SW48, SW480, SW837, T84     
14q32.33 105,305
,751 
106,342,077 1.04 0.4 – 1.3  
Colo201, Colo320DM, HCT116, HCT116 p53-
/-, HT29, NCI H508, SW837            
17q24.1 61,037,
879 
61,181,176 0.14 0.2 – 0.7  
Colo201, HCT116, HCT116 p53-/-, NCI H508, 
NCI H716, SK-CO-1, SW837              
17q25.1 70,481,
449 
70,707,547 0.23 0.3 – 1.0  
 
  
Table 2.  Summary of the regions having copy number losses  
 
   Cell lines containing deletions Cytoband Starting 
bp 
Ending bp Size 
(Mb) 
aCGH copy 
number 
deletions 
range (log2 
ratio) 
Candidate genes in the 
regions of copy number loss 
Colo201, Colo320DM, LS411N, NCI H508, 
SK-CO-1, SW480, T84 
2q23.3 15212841
9 
15231926
2 
0.2 -0.3 to -0.65 NEB 
Colo201, HCT116 p53-/-, HT29, LS411N, NCI 
H508, NCI H716, SW837 
3p14.2 60179044 60195847 0.02 -0.3 to -1.6 Intron of FHIT 
Colo201, HCT116, HCT116 p53-/- , HT29, 
LS411N, NCI H508, NCI H716, SW837 
3p14.2 60195847 60211085 0.02 -0.3 to -1.6 Intron of FHIT 
Colo201, HCT116, HCT116 p53-/- , HT29, 
LS411N, LoVo, NCI H508, NCI H716, SW837 
3p14.2 60211085 60366651 0.2 -0.3 to -3.0 Intron of FHIT 
Colo201, HCT116 p53-/- , HT29, LS411N, 
LoVo, NCI H508, NCI H716, SW480, SW837  
3p14.2 60366651 60600423 0.2 -0.3 to -3.0 FHIT 
Colo201, HCT116 p53-/- , HT29, LS411N, 
LoVo, NCI H508, NCI H716, SW837 
3p14.2 60600423 60601597 0.00
1 
-0.3 to -2.2 Intron of FHIT 
Colo201, Colo320DM, HCT116 p53-/- , HT29, 
LS411N, LoVo, NCI H508, NCI H716, SW837  
3p14.2 60601597 60659727 0.06 -0.3 to -2.2  Intron of FHIT 
Colo201, Colo320DM, HCT116 p53-/- , HT29, 
LS411N, NCI H716, SW837 
3p14.2 60659727 60699679 0.04 -0.3 to -2.2 Intron of FHIT 
Colo201, LS411N, LoVo, SK-CO-1, SW480, 
SW837, T84 
5q13.2 68918436 
 
69002998 
 
0.08 -0.4 to -0.7 SMA4, GTF2H2B, GTF2H2C, 
GTF2H2D, GTF2H2, 
GUSBP3, LOC100272216 
Colo201, Colo320DM, HT29, LS411N, LoVo, 
SK-CO-1, SW480, SW837, T84 
5q13.2 69002998 69127115 0.1 -0.4 to -0.7 contained within SMA4, region 
overlaps with 34.27% of 
GUSBP3 
Colo201, Colo320DM, HT29, LS411N, LoVo, 
SK-CO-1, SW48, SW480, SW837, T84 
5q13.2 69127115 69684303 0.6 -0.4 to -0.7  
Colo201, Colo320DM, HT29, LS411N, LoVo, 
SK-CO-1, SW480, SW837, T84 
5q13.2 69684303 
 
70543264 
 
0.9 -0.4 to -0.7 SMA4, GTF2H2B, GTF2H2C, 
GTF2H2D, SMA5, 
LOC441081, GUSBP9, 
SERF1A, SERF1B, SMN2, 
SMN1, NAIP, LOC647859 
Colo201, Colo320DM, HT29, LS411N, LoVo, 
SK-CO-1, SW480, SW837 
5q13.2 70543264 70669127 0.1 -0.4 to -0.7 GUSBP9 
HT29, NCI H508, NCI H716, SK-CO-1, 
SW480, SW837, T84 
8p23.1 6759882 
 
6779798 0.02 -0.3 to -1.4 DEFA6, region ends 957 bp 
before DEFA4 
Colo320DM, HT29, LS411N, NCI H508, NCI 
H716, SK-CO-1, SW480, SW837, T84 
8p23.1 6779798 6824457 0.04 -0.5 to -1.4 DEFA10P, DEFA4, region 
overlaps with 4.20% of 
DEFA1, region overlaps with 
  DEFA1B 
Colo201, Colo320DM, HT29, LS411N, NCI 
H508, NCI H716, SK-CO-1, SW480, SW837, 
T84 
8p23.1 6824457 
 
7196061 
 
0.4 -0.5 to -1.4  
Colo201, Colo320DM, HT29, LS411N, NCI 
H716, SK-CO-1, SW480, SW837, T84 
8p23.1 7196061 7243352 0.05 -0.5 to -1.2 ZNF705G, region  overlaps 
with  8.94% of FAM66B 
Colo201, Colo320DM, HT29, LS411N, NCI 
H716, SK-CO-1, SW48, SW480, SW837, T84 
8p23.1 7243352 7760349 0.5 -0.5 to -1.2  
Colo201, Colo320DM, HT29, LS411N, NCI 
H716, SK-CO-1, SW480, SW837, T84 
8p23.1 7760349 7767962 0.01 -0.5 to -1.2 region ends 8174 bp before 
DEFB103A 
Colo201, Colo320DM, HT29, NCI H716, SK-
CO-1, SW480, SW837, T84 
8p23.1 7767962 8024923 0.3 -0.4 to -1.2 DEFB103A, DEFB103B,
DEFB109P1B, DEFB4A, 
FAM66E, MIR548I3, 
USP17L3, USP17L8, 
ZNF705B  
HT29, LS411N, NCI H716, SK-CO-1, SW480, 
SW837, T84 
8p23.1 11368117 11512387 0.1 -0.3 to -1.0  BLK, LINC00208 
HT29, NCI H508, NCI H716, SK-CO-1, 
SW480, SW837, T84 
8p22 15174627 15414385 0.2 -0.3 to -0.8 region ends 27582 bp before 
TUSC3 
HCT116, HT29, LoVo, NCI H508, NCI H716, 
SW48, T84 
9p12 41613166 41759552 0.1 -0.4 to -1.1 region starts 30958 bp after 
ZNF658B 
Colo320DM, HCT116, HT29, LoVo, NCI H508, 
NCI H716, SW48, T84 
9p12-11.2 41759552 43003659 1.2 -0.4 to -1.1 MGC21881, KGFLP2, 
LOC643648, ANKRD20A2, 
ANKRD20A3, FAM95B1, 
FOXD4L4, FOXD4L2, 
LOC286297, AQP7P3 
Colo320DM, HT29, LoVo, NCI H508, NCI 
H716, SW48, T84 
9p11.2 43003659 
 
43678360 
 
0.7 -0.4 to -1.1 ANKRD20A2, ANKRD20A3, 
FAM95B1, LOC642929, 
FAM75A6, CNTNAP3B 
Colo320DM, HT29, LoVo, NCI H508, NCI 
H716, SW48, T84 
9p11.2 – 
q13 
43794421 
 
70017489 
 
26.2 -0.4 to -1.1 CNTNAP3B, LOC643648, 
FAM27C, FAM27A, KGFLP1, 
FAM74A4, FAM74A2, 
SPATA31A5, SPATA31A7, 
MGC21881, LOC28627, 
AQP7P1, FAM27B, 
ANKRD20A1, ANKRD20A3, 
LOC642236, LOC100132352, 
PGM5P2, LOC440896, 
FOXD4L6, CBWD6, 
ANKRD20A4, 
LOC100133920, FOXD4L5, 
FOXD4L2, FOXD4L4, 
CBWD3, CBWD5 
HT29, LS411N, LoVo, NCI H508, NCI H716, 
SW48, SW480, SW837, T84 
14q11.1-
q11.2 
18407780 19456314 1.0 -0.3 to -1.4 LOC642426, OR11H12, 
OR11H2,OR4K2, OR4M1, 
OR4N2, OR4Q3, POTEG, 
POTEM 
Colo201, DLD-1, LS411N, NCI H716, SW480, 
SW837, T84 
18q21.1 43485291 44789986 
 
1.3 -0.3 to -0.9 CTIF, MIR4743, SMAD2, 
SMAD7, ZBTB7C 
Colo201, LS411N, NCI H508, NCI H716, 
SW480, SW837, T84 
18q21.1 45939166 
 
46237377 
 
0.3 -0.4 to -0.9 CCDC11, CXXC1, MBD1, 
SKA1, region overlaps with 
12.17% of MYO5B 
Colo201, LS411N, NCI H716, SK-CO-1, 
SW480, SW837, T84 
18q21.2 47301645 49512571 2.2 -0.4 to -0.9 DCC, region overlaps with 
1.86% of LOC100287225 
Colo201, LS411N, NCI H716, SK-CO-1, 
SW480, SW837, T84 
18q21.2-
q23 
51105332 
 
76108541 
 
25.0 -0.4 to -1.1 TCF4, MIR4529, 
LOC100505474, TXNL1, 
WDR7, LINC-ROR, BOD1L2, 
ST8SIA3, ONECUT2, FECH, 
NARS, LOC100505549, 
ATP8B1, NEDD4L, MIR122, 
MIR3591, ALPK2, MALT1, 
ZNF532, OACYLP, SEC11C, 
GRP, RAX, CPLX4, LMAN1, 
CCBE1, PMAIP1, MC4R, 
CDH20, RNF152, PIGN, 
KIAA1468, TNFRSF11A, 
ZCCHC2, PHLPP2, BCL2, 
KDSR, VPS4B, SERPINB5, 
SERPINB12, SERPINB13, 
SERPINB4, SERPINB3, 
SERPINB11, SERPINB7, 
SERPINB2, SERPINB10, 
HMSD, SERPINB8, 
LINC00305, LOC284294, 
LOC400654, CDH7, CDH19, 
MIR5011, DSEL, LOC643542, 
TMX3, CCDC102B, DOK6, 
CD226, RTTN, SOCS6, 
LOC100505776, CBLN2, 
NETO1, LOC400655, 
LOC100505817, FBX015, 
TIMM21, CYB5A, C18ORF63, 
FAM69C, CNDP2, CNDP1, 
LOC400657, ZNF407, ZADH2, 
TSHZ1, C18ORF62, 
LOC339298, ZNF516, 
FLJ44313, LOC284276, 
LOC100131655, ZNF236, 
MBP, GALR1, SALL3, ATP9B, 
NFATC1, CTDP1, KCNG2, 
PQLC1, HSBP1L1, TXNL4A, 
RBFA, ADNP2, PARD6G-
AS1, PARD6G 
Colo201, HT29, NCI H508, NCI H716,  
SW480, SW837, T84 
20p12.1 14636068 14938351 0.3 -0.4 to -3.2 MACROD2 
 
 
 
 
 
 
 
Figure legends 
Fig. 1 A. Waterfall plot for the 5-fluorouracil IC50 (µM) values.  B. Waterfall plot for 
oxaliplatin IC50 (µM) values.  C. Waterfall plot for BEZ235 IC50 (nM) values.  D. 
Unsupervised hierarchical clustering for the IC50 values for 5-FU, L-OHP and 
BEZ235 using Pearson’s Correlation with complete linkage. 
Fig. 2.  Karyogram for chromosome 1 to 22 showing the most frequent gains and 
losses for the 15 CRC cell lines   
Fig. 3.  Hierarchical clustering using the genomic segmentations of the 15 CRC cell 
lines. 
Fig. 4.  A. A heatmap depicting the SAM analysis for genes differentially expressed 
between 5-FU sensitive and less sensitive CRC cell lines; B. A heatmap depicting 
the SAM analysis for genes differentially expressed between L-OHP sensitive and 
less sensitive CRC cell lines; C. A heatmap depicting the SAM analysis for genes 
differentially expressed between BEZ235 sensitive and less sensitive CRC cell lines. 
Fig. 5. Venn diagram showing differentially expressed genes with respect to 
treatment response to a) 5-FU, b) L-OHP, and c) BEZ235B.   
Fig. 6. Unsupervised hierarchical clustering for the 47 candidate genes annotated 
according to response to therapy. 
Fig. 7.  Unsupervised hierarchical clustering of RPPA protein expression data using 
Euclidian distance with average linkage. 
Fig. 8. A. Box plots showing significant differences in protein expression between 5-
FU sensitive and less sensitive cell lines (Mann Whitney U test)  B. Box plots 
showing significant differences in protein expression between L-OHP sensitive and 
less sensitive cell lines (Mann Whitney U test). 
Fig. 9. Spearman’s correlation network using Bonferroni Correction (p = 0.05) and 
circular network layout (http://www.tmanavigator.org/). Abbreviations: N - nucleus, C 
– cytoplasm. 









